Name: BPC-157 / TB-500 Blend 10mg
Brand: RetaLABS
SKU: bpc-157-tb-500-blend-10mg
Price: 85.00 AUD
Availability: InStock
Rating: 4.8 (6 reviews)

Question 1

What is the BPC-157 / TB-500 blend used for in research?

Accepted Answer

The BPC-157 / TB-500 blend is used in preclinical research investigating whether the combined administration of two mechanistically distinct tissue-repair peptides produces additive or synergistic outcomes compared to either compound alone. BPC-157 (Body Protection Compound-157) is researched primarily for its effects on angiogenesis, fibroblast activity, nitric oxide modulation, and gut mucosal protection. TB-500 (the active Thymosin Beta-4 fragment Ac-LKKTETQ) modulates G-actin sequestration and cell migration through its actin-binding domain, promoting satellite cell activation in muscle tissue and endothelial cell migration in vascular repair models. The rationale for combining them is that BPC-157 operates largely through growth factor and NO-mediated mechanisms, while TB-500 acts via cytoskeletal remodelling and actin dynamics — two non-overlapping pathways. Research using this blend examines whether addressing both mechanisms simultaneously produces superior tissue repair outcomes in tendon, muscle, and wound healing models.

Question 2

What is TB-500 in this blend?

Accepted Answer

TB-500 in this context refers specifically to the biologically active fragment of Thymosin Beta-4 — the heptapeptide sequence Ac-LKKTETQ, which contains the actin-binding domain responsible for the peptide's observed biological activity in research models. It is structurally and functionally distinct from the full 43-amino-acid Thymosin Beta-4 protein. The actin-binding activity of this fragment is well characterised: the TB-500 fragment sequesters G-actin (globular actin monomers), preventing their polymerisation into F-actin filaments and thereby regulating the actin equilibrium that governs cell motility, shape, and division. In wound healing and tissue repair research, this mechanism translates to enhanced migration of endothelial cells, keratinocytes, and cardiac cells into repair zones. The truncated fragment retains the key Ac-LKKTETQ actin-binding sequence while offering improved solubility and ease of synthesis compared to the full Tβ4 protein, making it the standard form used in most published preclinical research.

Question 3

How should the blend be reconstituted?

Accepted Answer

Reconstitute the BPC-157 / TB-500 blend with bacteriostatic water using standard lyophilised peptide reconstitution technique. Draw the required volume of bacteriostatic water into a syringe and inject it slowly along the inner glass wall of the vial, allowing the diluent to run down the side and contact the powder gently — do not inject directly onto the lyophilised cake. Gently swirl the vial in circular motions until the powder is fully dissolved; avoid vigorous shaking, which can cause peptide aggregation in either component. Because this is a co-lyophilised blend, both peptides dissolve from the same powder cake — there is no need for sequential reconstitution or separate vials. Once dissolved, the solution should be clear; discard if cloudiness or visible particulates are observed. Store reconstituted solution at 2–8°C and use within four weeks. Keep unreconstituted vials at −20°C until required.

Question 4

Why choose the blend over individual vials?

Accepted Answer

The BPC-157 / TB-500 blend simplifies research protocols that require simultaneous delivery of both compounds in a consistent molar ratio. Rather than managing two separate vials, two separate reconstitutions, and potential errors in combining volumes at the correct ratio, the co-lyophilised blend provides a single reconstitution step with a guaranteed 1:1 mass ratio of BPC-157 to TB-500 in every preparation. This consistency is valuable for multi-session research studies where reproducibility of compound ratios across experimental groups is important. The blend is particularly practical for researchers new to these peptides who want to study the combined mechanism before optimising individual dosing ratios. Individual vials offer greater flexibility when your research protocol requires different BPC-157 to TB-500 ratios — for example, if preliminary data suggests one compound is more relevant to your model and you want to titrate independently.

BPC-157 / TB-500 Blend 10mg

Customer Reviews

Product Specifications

Frequently Asked Questions

Research Guides